Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119198) titled 'The Diagnostic Value and Therapeutic Response Assessment of FAPI PET in Newly Diagnosed Prostate Cancer' on Feb. 24.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Condition:
untreated high risk hormone-sensitive prostate cancer (PSA > 20 / Gleason score > 7 / T stage> cT2c)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-05-01
Target Sample Size: Observation Group:60;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=...